Assessment of Ergonomics in 3D vs 2D Thoracoscopic Lobectomy

Sponsor
University of Rome Tor Vergata (Other)
Overall Status
Completed
CT.gov ID
NCT03925103
Collaborator
(none)
70
1
2
15
4.7

Study Details

Study Description

Brief Summary

Video-assisted thoracic surgery (VATS) pulmonary lobectomy is currently widely employed as the first treatment option for surgical management of early stage (stage I-II) non-small-cell-lung-cancer (NSCLC).

Thanks to recent technological advances in high definition display systems, three dimensional VATS (3D) has been developed in an attempt of overcoming some optical limits of two dimensional (2D) VATS.

In this single center randomized trial our aim is to comparatively assess ergonomics of 3D versus 2D VATS lobectomy for early stage NSCLC.

Condition or Disease Intervention/Treatment Phase
  • Procedure: 3D VATS lobectomy
  • Procedure: 2D VATS lobectomy
N/A

Detailed Description

Video-assisted thoracic surgery (VATS) is widely employed for pulmonary lobectomy in early stage non-small-cell-lung-cancer (NSCLC). Indeed, VATS is thought to represent an optimal minimally invasive surgical option which is deemed superior to conventional thoracotomy since it enables smaller incisions with no rib spreading thus minimizing both postoperative pain and hospital stay.

For over than three decades, several thoracic surgeons adopted VATS for anatomical lung resection using two-dimensional (2D) display systems. However, a 2D image lacks depth of perception which may negatively affect surgical manoeuvring.

Three dimensional (3D) display systems for VATS can offer superior magnified vision of the surgical field and better perception of depth during surgical manoeuvring potentially shortening learning curve, which may thus overcome some optical limitations of 2D systems.

In this single center randomized trial our aim is to comparatively assess ergonomics of 3D versus 2D VATS lobectomy for early stage (stage I-II) NSCLC. For this purpose we compared three ergonomical domains: exposure, instrumentation and maneuvering with the aid of a scoring scale entailing analysis of 5 main technical steps: vein, artery bronchus, lymph node and fissure score.

The evaluation process of the five surgical steps was carried out by 4 thoracic surgeons who individually scored all recorded operations.

Study Design

Study Type:
Interventional
Actual Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
One to one parallel assignment to each treatmentOne to one parallel assignment to each treatment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy for Lung Cancer
Actual Study Start Date :
Oct 1, 2018
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3D VATS lobectomy

Patients undergo thoracoscopic lobectomy by a three-dimensional display system

Procedure: 3D VATS lobectomy
pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system

Active Comparator: 2D VATS lobectomy

Patients undergo thoracoscopic lobectomy by a two-dimensional display system

Procedure: 2D VATS lobectomy
pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system

Outcome Measures

Primary Outcome Measures

  1. a difference ≥10% in the score calculated for the maneuvring ergonomical domain. [one week after surgery]

    3 ergonomical domains: exposure, instrumentation and maneuvering are assessed by 4 thoracic surgeons using a new scoring scale (score range 1, unsatisfactory to 3 excellent). Primary outcome is a difference ≥10% (sd=0.3) in at least one of the evaluated domains.

Secondary Outcome Measures

  1. Operative time [during surgery]

    Total duration (min) of the surgical procedure from first incision opening to last incision closure

  2. intraoperative bleeding [intraoperative]

    Total amount of blood (mL) lost during the surgical procedure

  3. postoperative drainage volume [two weeks after surgery]

    Total amount of fluid (mL) collected through the chest drain during in-hospital stay

  4. surgical mortality [90 days after surgery]

    Fatal complications occurryng within 90 days after surgery

  5. complications [30 days after surgery]

    Any adverse event recorded perioperatively or after the surgical procedure during in-hospital stay

  6. hospital stay [30 days after surgery]

    Overall duration (days) of in-hospital stay after the surgical procedure

  7. a difference ≥10% in the score calculated for the exposure ergonomical domain. [one week after surgery]

    3 ergonomical domains: exposure, instrumentation and maneuvering are assessed by 4 thoracic surgeons using a new scoring scale (score range 1, unsatisfactory to 3 excellent). Primary outcome is a difference ≥10% (sd=0.3) in at least one of the evaluated domains.

  8. a difference ≥10% in the score calculated for the instrumentation ergonomical domain. [one week after surgery]

    3 ergonomical domains: exposure, instrumentation and maneuvering are assessed by 4 thoracic surgeons using a new scoring scale (score range 1, unsatisfactory to 3 excellent). Primary outcome is a difference ≥10% (sd=0.3) in at least one of the evaluated domains.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical NSCLC early stage (stage I-II).

  • Both forced expiratory volume in one second (FEV1) and diffusion capacity of carbon monoxide (DLCO)>60%

  • Both predicted postoperative (PPO) FEV1 and PPO DLCO >35%

  • American Society of Anesthesia (ASA) score<=2

  • Body mass index (BMI) >18 <28

Exclusion Criteria:
  • Clinical NSCLC stage> II

  • History of Neoadjuvant chemotherapy or radiotherapy

  • Radiologic evidence of extensive pleural adhesions.

  • Age <18 or >80 years.

  • Patients with previous pleurodesis or thoracotomy in the affected hemithorax.

  • Patients who will undergo surgical lung resection other than lobectomy.

  • Patients with severe comorbidity contraindicating lobectomy.

  • Patients refusal or noncompliance to general surgery and one-lung ventilation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Policlinico Tor Vergata University Roma Italy 00133

Sponsors and Collaborators

  • University of Rome Tor Vergata

Investigators

  • Principal Investigator: Eugenio Pompeo, MD, Tor Vergata University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Eugenio Pompeo, Principal Investigator, University of Rome Tor Vergata
ClinicalTrials.gov Identifier:
NCT03925103
Other Study ID Numbers:
  • 2019-1RT
First Posted:
Apr 23, 2019
Last Update Posted:
Apr 8, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eugenio Pompeo, Principal Investigator, University of Rome Tor Vergata
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2020